Hausner et al., 2009 - Google Patents
Synthesis of 5-and 6-substituted 2-(4-dimethylaminophenyl)-1, 3-benzoxazoles and their in vitro and in vivo evaluation as imaging agents for amyloid plaqueHausner et al., 2009
View HTML- Document ID
- 16823994236414364029
- Author
- Hausner S
- Alagille D
- Koren A
- Amici L
- Staley J
- Cosgrove K
- Baldwin R
- Tamagnan G
- Publication year
- Publication venue
- Bioorganic & medicinal chemistry letters
External Links
Snippet
A series of novel 5-and 6-substituted 2-(4-dimethylaminophenyl)-1, 3-benzoxazoles was synthesized and their potential as imaging probes for Alzheimer's Disease (AD)-related amyloid plaque was evaluated in vitro and in vivo. In vitro binding affinities for Aβ1–40 …
- -1 6-substituted 2-(4-dimethylaminophenyl)-1, 3-benzoxazoles 0 title abstract description 17
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001286702B2 (en) | Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease | |
ES2767973T3 (en) | Contrast agents for applications involving perfusion imaging | |
US8168800B2 (en) | Aβ-binding small molecules | |
Wang et al. | Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease | |
CN109475648B (en) | Compounds for imaging TAU protein aggregates | |
Cui et al. | Novel quinoxaline derivatives for in vivo imaging of β-amyloid plaques in the brain | |
Hausner et al. | Synthesis of 5-and 6-substituted 2-(4-dimethylaminophenyl)-1, 3-benzoxazoles and their in vitro and in vivo evaluation as imaging agents for amyloid plaque | |
US20210017133A1 (en) | Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging | |
Kaide et al. | 18F-labeled benzimidazopyridine derivatives for PET imaging of tau pathology in Alzheimer’s disease | |
US20090123373A1 (en) | Amyloid-imaging agents | |
Cui et al. | 99mTc-and Re-labeled 6-dialkylamino-2-naphthylethylidene derivatives as imaging probes for β-amyloid plaques | |
Chen et al. | Synthesis of 11C-labeled DNA polymerase-β inhibitor 5-methoxyflavone and PET/CT imaging thereof | |
CA2911307C (en) | Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging | |
Qu et al. | Radioiodinated aza-diphenylacetylenes as potential SPECT imaging agents for β-amyloid plaque detection | |
Akasaka et al. | Synthesis and evaluation of novel radioiodinated phenylbenzofuranone derivatives as α-synuclein imaging probes | |
Duan et al. | Aβ-binding molecules: Possible application as imaging probes and as anti-aggregation agents | |
US20220372045A1 (en) | Deuterated compounds and imaging agents for imaging huntingtin protein | |
Quinlivan et al. | Synthesis and evaluation of iodine-123 labelled tricyclic tropanes as radioligands for the serotonin transporter | |
AU2015200027B2 (en) | Contrast agents for applications including perfusion imaging | |
Kallinen et al. | Synthesis and biological evaluation of novel 123I-labeled 4-(4-iodophenyl) butanoyl-l-prolyl-(2S)-pyrrolidines for imaging prolyl oligopeptidase in vivo | |
Désogère et al. | Optimization of a collagen-targeted positron emission tomography probe for molecular imaging of pulmonary fibrosis. | |
TW201922296A (en) | Preparation of [18F]T807 derivatives and uses thereof |